Dr. Martin Gleave

Dr. Martin Gleave

B.Sc. Physical Education, University of British Columbia
Doctor of Medicine, University of British Columbia
Fellow of the Royal College of Surgeons of Canada
Fellow, American College of Surgeons
Order of Canada

Team: 
Board of Directors
Clinical and Research Scientists
Executive Team
Positions: 

Executive Director, Vancouver Prostate Centre
Chief Executive Officer, PC-TRiADD
Distinguished Professor and Head, Department of Urologic Sciences, UBC
BC Leadership Chair in Prostate Cancer Research

 

Dr. Gleave (CM, MD, FRCSC, FACS) is a clinician-scientist and urologic surgeon. His major research focus involves the study of cellular and molecular mechanisms mediating progression of prostate cancer to its lethal stage of androgen independence, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. Dr Gleave established a role for clusterin as a cancer-related cell survival protein involved in treatment resistance and developed an inhibitor, designated OGX-011, which improved efficacy of hormone- and chemo-therapies in prostate and other cancer models. He is the scientific founder of OncoGenex Pharmaceuticals Inc. and a Member of the Order of Canada.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC took place on Sunday June 16, 2019 in various locations across BC. The sponsorship page is still accepting donations;  click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Monday, July 8, 2019

Dr. Flannigan to lead clinical trial for scrotal pain treatment

Dr. Flannigan
Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi